Rallybio Corporation
NASDAQ:RLYB
Overview | Financials
Company Name | Rallybio Corporation |
Symbol | RLYB |
Currency | USD |
Price | 0.95 |
Market Cap | 39,413,220 |
Dividend Yield | 0% |
52-week-range | 0.93 - 3.46 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Stephen Uden M.B, M.D. |
Website | https://www.rallybio.com |
An error occurred while fetching data.
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD